HOME >> MEDICINE >> NEWS
US FDA grants full approval to DOXIL(R) following submission of phase III data

Bridgewater, N.J. February 7, 2005 -- The U.S. Food and Drug Administration (FDA) has granted full approval to DOXIL (doxorubicin HCl liposome injection) for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. DOXIL, marketed in the United States by Tibotec Therapeutics, Division of Ortho Biotech Products, L.P., originally received accelerated approval for refractory ovarian cancer in June 1999. As a result of the full approval, the product label for DOXIL has been updated to include survival, time to disease progression and tumor response rate data from a randomized Phase III clinical study.

Under accelerated approval, DOXIL was indicated for the treatment of metastatic ovarian cancer in patients with disease that was refractory to both paclitaxel- and platinum-based chemotherapy regimens. This approval was based on tumor response rates from three Phase II studies. According to the terms of the accelerated approval, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) completed a randomized Phase III clinical study to formally demonstrate the drug's clinical benefit in patients with relapsed ovarian cancer. In March 2004, J&JPRD submitted a supplemental new drug application (sNDA) based on data from the Phase III study.

"The Phase III data provide evidence of the product's clinical benefit for patients with relapsed ovarian cancer," commented Alan N. Gordon, M.D., of the University of Arizona School of Medicine and Arizona Gynecologic Oncology, in Phoenix, Ariz., and lead author of the Phase III study, known as DOXIL Study 30-49.

In the randomized, multi-center, open-label, Phase III study, 474 patients with recurrent epithelial ovarian cancer were randomly assigned to receive either DOXIL 50 mg/m2 every 28 days or topotecan HCl 1.5 mg/m2/day for five consecutive days every 21 days. A total of 239 patients received DOXIL; 235 patients received
'"/>


7-Feb-2005


Page: 1 2 3

Related medicine news :

1. UNH launches 2nd spinout company with NIH grants
2. Disease testing for immigrants: Discrimination disguised as public health policy
3. Four teams awarded inaugural translational cancer research grants
4. Immigrants, beware: Living in the United States is fattening
5. Prevalence of obesity among immigrants increases with longer residency in US
6. FDA grants accelerated approval of TYSABRI, formerly antegren, for the treatment of MS
7. Dana-Farber receives CDC grants to develop health promotion/prevention programs in the work place
8. Speech recognition experts at OGI School of Science & Engineering receive nearly $700,000 in grants
9. Should compulsory screening of immigrants be part of UK public health policy?
10. NIH grants support health disparities biomedical research
11. NCCAM awards planning grants for International Centers for Research

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA grants full approval DOXIL following submission phase III data

(Date:4/28/2015)... Hellen Chen, who is a bestselling author and ... to a study conducted by Washington University, between ... has increased by 20% while the number of unfaithful husbands ... report released this year from the Journal of ... or both spouses admit to infidelity, either physical or emotional ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 Researchers from ... one dose of a steroid prior to pemetrexed (Alimta) ... skin reaction. Click here to read the full ... Scientists from the Raabe College of Pharmacy in Ohio, ... and Appalachian Regional Healthcare in Kentucky gave a single ...
(Date:4/28/2015)... 28, 2015 The buyer power score ... of 5, indicating a medium level of buyer power ... suppliers have equal power during negotiations. One factor helping ... purchasing a health insurance policy from an insurance carrier ... buyers can choose to self-fund their own policy or ...
(Date:4/28/2015)... Louis, Missouri (PRWEB) April 28, 2015 ... report that delves into the reality problem Americans have ... the population will need long-term care services as they ... need such care. , In the report, Carol ... organizations such as the American Health Care Association and ...
(Date:4/28/2015)... OsteoRemedies®, LLC, Memphis, TN, offers ... of infected hip and knee arthroplasty. ... pre-formed, pre-loaded spacer with Gentamicin Antibiotics, for consistent ... Combined with a consistent process for polishing ... approved for temporary use for up to 180 ...
Breaking Medicine News(10 mins):Health News:Why Do Some Good Women and Men End Up Breaking Others' Marriages? 2Health News:Why Do Some Good Women and Men End Up Breaking Others' Marriages? 3Health News:Study Finds New Regimen May Ward Off Skin Rash from Common Mesothelioma Drug, According to Surviving Mesothelioma 2Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 2Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 4Health News:SeniorCare.com Report: America Has a Major Misconception on Aging 2
(Date:4/28/2015)... , April 28, 2015 ANI Pharmaceuticals, ... Company plans to release its first quarter 2015 financial ... of the U.S. financial markets. The earnings press release ... the Company,s website, www.anipharmaceuticals.com . ... Officer, and Charlotte C. Arnold , Vice President ...
(Date:4/28/2015)... CARLOS, Calif. , April 28, 2015  Rosa ... expertise in drug-disease modeling and simulation, today announced its ... in the exciting field of Quantitative Systems Pharmacology (QSP). ... in pharmaceutical drug development.  ... Rosa,s ...
(Date:4/28/2015)...  Boston Scientific Corporation (NYSE: BSX ) ... quarter ended March 31, 2015, compared to the ... to $1.800 billion.  This represents 6 percent operational ... and flat revenue on a reported basis, all ... achieved adjusted earnings per share of $0.21 for ...
Breaking Medicine Technology:ANI Pharmaceuticals Schedules Conference Call for First Quarter 2015 Financial Results 2Rosa & Co. is the Lead Partner for the Quantitative Systems Pharmacology (QSP) Congress in Basel, Switzerland and Will Present the Keynote Address 2Rosa & Co. is the Lead Partner for the Quantitative Systems Pharmacology (QSP) Congress in Basel, Switzerland and Will Present the Keynote Address 3Boston Scientific Announces Results for First Quarter 2015 2Boston Scientific Announces Results for First Quarter 2015 3Boston Scientific Announces Results for First Quarter 2015 4Boston Scientific Announces Results for First Quarter 2015 5Boston Scientific Announces Results for First Quarter 2015 6Boston Scientific Announces Results for First Quarter 2015 7Boston Scientific Announces Results for First Quarter 2015 8Boston Scientific Announces Results for First Quarter 2015 9Boston Scientific Announces Results for First Quarter 2015 10Boston Scientific Announces Results for First Quarter 2015 11Boston Scientific Announces Results for First Quarter 2015 12Boston Scientific Announces Results for First Quarter 2015 13Boston Scientific Announces Results for First Quarter 2015 14Boston Scientific Announces Results for First Quarter 2015 15Boston Scientific Announces Results for First Quarter 2015 16Boston Scientific Announces Results for First Quarter 2015 17Boston Scientific Announces Results for First Quarter 2015 18Boston Scientific Announces Results for First Quarter 2015 19Boston Scientific Announces Results for First Quarter 2015 20Boston Scientific Announces Results for First Quarter 2015 21Boston Scientific Announces Results for First Quarter 2015 22Boston Scientific Announces Results for First Quarter 2015 23Boston Scientific Announces Results for First Quarter 2015 24Boston Scientific Announces Results for First Quarter 2015 25
Cached News: